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Abstract
Background: ERBB2 is overexpressed in up to 20–30% of human breast cancers (BCs), and it is associated with
aggressive disease. Trastuzumab (Tz), a humanized monoclonal antibody, improves the prognosis associated with
ERBB2-amplified BCs. However, the development of resistance remains a significant challenge. Carnosic acid
(CA) is a diterpene found in rosemary and sage, endowed with anticancer properties. In this in vitro study,
we have investigated whether Tz and CA have cooperative effects on cell survival of ERBB2 overexpressing
(ERBB2+) cells and whether CA might restore Tz sensitivity in Tz-resistant cells.
Methods: We have studied BC cell migration and survival upon CA and Tz treatment. In particular, migration
ability was assessed by transwell assay while cell survival was assessed by MTT assay. In addition, we have performed cell
cycle and apoptosis analysis by high-resolution DNA flow cytometry and annexin-V, resazurin and sytox blue staining by
flow cytometry, respectively. The expression of proteins involved in cell cycle progression, ERBB2 signaling
pathway, and autophagy was evaluated by immunoblot and immunofluorescence analysis. Cellular structures
relevant to the endosome/lysosome and autophagy pathways have been studied by immunofluorescence and
transmission electron microscopy.
Results: We report that, in ERBB2+ BC cells, CA reversibly enhances Tz inhibition of cell survival, cooperatively
inhibits cell migration and induces cell cycle arrest in G0/G1. These events are accompanied by ERBB2 down-
regulation, deregulation of the PI3K/AKT/mTOR signaling pathway and up-regulation of both CDKN1A/p21WAF1
and CDKN1B/p27KIP1. Furthermore, we have demonstrated that CA impairs late autophagy and causes derangement of
the lysosomal compartment as shown by up-regulation of SQSTM1/p62 and ultrastructural analysis. Accordingly, we
have found that CA restores, at least in part, sensitivity to Tz in SKBR-3 Tz-resistant cell line.
Conclusions: Our data demonstrate the cooperation between CA and Tz in inhibiting cell migration and survival of
ERBB2+ BC cells that warrant further studies to establish if CA or CA derivatives may be useful in vivo in the treatment
of ERBB2+ cancers.
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Background
ERBB2 is a member of the epidermal growth factor (EGF)
receptor (ERBB1) family and is chaperoned by HSP90; un-
like other ERBB members (ERBB1, ERBB3 and ERBB4),
ERBB2 has no soluble ligands [1]. ERBB2 is amplified and
overexpressed in 20% to 30% of human breast cancers
(BCs), and it is often associated with aggressive disease
and poor prognosis [2, 3]. Trastuzumab (Tz, Herceptin®),
a humanized monoclonal antibody [4], binds the extracel-
lular region of ERBB2 and inhibits receptor signaling via
several mechanisms, including the down-regulation of
both the Ras/Raf/MAPK pathway, which contributes to
cell proliferation [5], and the PI3K/AKT pathway, which
regulates cell survival [6, 7]. Moreover, nuclear accumula-
tion of the cell cycle inhibitor CDKN1B/p27KIP1, and cell
cycle arrest have been reported [8, 9]. The introduction of
Tz therapy and, more recently, of the first successful
HER2-targeted antibody–drug conjugate (ADC), trastuzu-
mab emtansine (T-DM1; Kadcyla; Genentech) have im-
proved significantly progression free survival and overall
survival in ERBB2-amplified metastatic BCs [10]. Neverthe-
less, the presence of primary and acquired resistance, as
well as serious adverse side effects to Tz and T-DM1 treat-
ments remain a significant common challenge [11, 12].
The catabolic process of autophagy is considered to be
associated with resistance to chemotherapy and targeted
inhibitors in cancers [13]. Indeed, autophagy induced by
anti-ERBB2 targeting agents like Tz and Lapatinib may
allow cancer cells to survive the stress induced by the
therapy [14, 15]. Thus, the inhibition of autophagy after
treatment with Tz resulted in apoptotic cell death [16].
Rosemary (Rosmarinus officinalis) and common sage
(Salvia officinalis) contain multiple bioactive components
including carnosic acid (CA), rosmarinic acid, carnosol,
caffeic acid, and ursolic acid, which have antioxidant,
antinflammatory, anti-steatosis and anticancer proper-
ties [17–19]. Whole extracts and/or purified compo-
nents isolated from rosemary have been shown to
inhibit the in vitro and in vivo cell growth from solid
tumors including BCs and leukemia cells [17]. The bio-
logical effects of CA on the modulation of cell cycle ar-
rest, apoptosis and autophagy programs have been
studied in different cancer cell types [17]. CA-mediated
inhibition of the PI3K/AKT/mTOR pathway and induc-
tion of autophagy have been observed in hepatocarci-
noma cells [20]. At difference, in myeloid leukemia
cells the inhibition of AKT signaling has induced
p27KIP1 expression and a block in the G1 phase of the
cell cycle [20]. In colon adenocarcinoma cells, CA re-
duced leptin signaling through dephosphorylation of
AKT, ERK and Insulin-like growth factor-I receptor,
which have caused a reduced expression of both BCL-
XL and Cyclin D1 resulting in cell cycle arrest [21]. In-
duction of apoptosis through the production of reactive
oxygen species (ROS) or mediated by the AKT/IKK/
NF-kB axis has been reported in different carcinoma
cell lines [17, 22]. In contrast, in human glioblastoma
(GBM) cell lines CA did not down-regulate the PI3K/
AKT pathway, whereas it induced proteasomal down-
regulation of Retinoblastoma, Cyclin B1, SOX2 and
GFAP and cell cycle arrest with only a minor induction
of apoptosis [23]. Therefore, these evidences corrobor-
ate the notion that CA does not elicit a common re-
sponse but down-modulates distinct cellular pathways
depending on a cancer cell-type specific context. In
particular, in BC cell lines, a previous study showed
that CA inhibited cell growth and suggested that
ERBB2 was required for this activity [24]. Others re-
ported that rosemary extract enhanced Tz effects on sur-
vival inhibition [25]. However, neither the active
compound nor the molecular mechanisms at the basis of
this interaction were provided.
In the present study, we aimed at investigating the
mechanisms of action and the potential benefit of the
combined treatment of CA and Tz in vitro in ERBB2+
BC cell lines SKBR-3 and BT474, which are sensitive to
Tz, and in Tz-resistant SKBR-3 cells. We have found
that CA exerts a reversible cooperation with Tz in boost-
ing the inhibition of cell survival and cell migration, by
inducing cell cycle arrest in G0/G1 phase. These events
are coupled with the down-regulation of PI3K/AKT/
mTOR pathway, the inhibition of late autophagy and de-
rangement of the endolysosomal compartment. In addition,
we have shown for the first time that co-treatment with CA
and Tz partially restored the sensitivity to Tz in Tz-resistant
SKBR-3 BC cells. These results suggest that a combined
therapy of CA and Tz could represent a new and poten-
tially less toxic approach worth of further investigations for
the treatment of ERBB2+ BCs.
Methods
Plant material
Fresh aerial parts of Salvia somalensis Vatke were ob-
tained from Centro Regionale di Sperimentazione ed
Assistenza Agricola (Albenga, Italy). All reagents were
analytical or high performance liquid chromatography
(HPLC) grade. The isolation of the leaf constituents of
Salvia somalensis (1.15 Kg) was performed following a
procedure previously described [26]. Carnosic acid (CA),
m.p. 190–192 °C was identified by comparison of its phys-
ical and spectroscopic data with those published in the
literature [27] and obtained with a HPLC purity of 95%.
Cell culture and drug treatments
BC cell lines SKBR-3, BT474, MCF7 and MDA-MB-231
were obtained from Banca Biologica and Cell Factory in
IRCCS AOU San Martino – IST belonging to the European
Culture Collection’s Organization. Tz resistant SKBR-3 (Tz-
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Res SKBR-3) cells were generated by continuous treatment
of SKBR-3 cells with Tz 200 μg/ml for 10 months. MCF10A
cells were obtained from NIH Institute and cultured
according to the manufacturer’s instructions.
BC cells were cultured in complete medium (DMEM
high glucose supplemented with 10% heat-inactivated fetal
bovine serum, 1% glutamine, penicillin and streptomycin
(Euroclone S.p.A., Milan, Italy). Tz (Genentech-Roche,
South San Francisco, CA, USA) was donated by the
UFA-Unità Farmaci Antiblastici of the IRCCS AOU -
San Martino - IST. Tz was used at a concentration of
10 μg/ml for SKBR-3 (parental and Tz-resistant),
MDA-MB-231 and MCF7 cells and at 0.24 μg/ml for
BT474, respectively. CA was used at 27.5 μM for
SKBR-3 (parental and Tz-resistant), MDA-MB-231 and
MCF7 cells and 37.5 μM for BT474, respectively. Con-
trol cultures were challenged with DMSO (CA solvent)
and human IgGs. Similarly, CA treated culture were
also exposed to human IgGs and Tz treated cultures to
DMSO, respectively.
Cell survival assay
All BC cells were plated in 24-well plates in complete
medium (triplicate of SKBR-3, BT474 and MDA-MB-
231 28,000 cells/well, MCF7 15,000 cells/well) and CA
and/or Tz were administered every 48 h for up to 7 or
10 days (d) as indicated. Cell survival was measured at
different time points using the 3-(4,5-dimethylthiazol-
2yl)-2,5-diphenyltetrazolium bromide (MTT) or Alamar
Blue (Thermo Fisher Scientific, Waltham, MA, USA)
colorimetric assay as described before [28], and as indi-
cated in the manufacturer’s instructions, respectively.
Cell migration assay
Cell migration assay was performed in quadruplicate
using 8.0 μm pore size inserts in 24-well plates (BD
Bioscience, Franklin Lakes, NJ). Fifty thousands MDA-
MB-231 cells and 150,000 BT474 cells were seeded in
the upper chamber and overnight starved (DMEM sup-
plemented with 1% glutamine, penicillin and strepto-
mycin). The day after, starvation medium was replaced,
in the lower chamber, with complete medium supple-
mented with CA for MDA-MB-231 cells or CA and/or
Tz for BT474 cells. Migrated cells were stained with
Crystal Violet after 48 h for MDA-MB-231 cells and
after 7d for BT474 cells (treatments every 48 h). Cell
migration was quantified using ImageJ [29] as previ-
ously described [30].
Flow cytometry (FCM) analysis
BT474 and SKBR-3 cells were treated with CA and/or
Tz for 48 h. Both adherent and floating cells were then
collected and centrifuged at 980 g for 5 min. Cell cycle
analysis was performed through evaluation of DNA
content in cell nuclei stained with DAPI by high reso-
lution DNA flow cytometry (hr DNA-FCM) using a
CyFlow ML flow cytometer (Sysmex-Partec Inc., Lin-
colnshire, IL, USA) [31]. Metabolic active, apoptotic and
necrotic cells were evaluated using a Cyan ADP flow cyt-
ometer (Beckman Coulter, Brea, CA, USA) and the
Vybrant® Apoptosis Assay Kit (Thermo Fisher Scientific)
with a minor modification as we used the nuclear stain-
ing fluorochrome sytox blue (Thermo Fisher Scientific)
in place of the sytox green.
Antibodies
All primary antibodies used are listed in Additional file 1:
Table S1.
Immunofluorescence analysis
SKBR-3, BT474 and MCF10A cells were treated for 7d
with CA and/or Tz (treatments every 48 h), fixed in 3%
paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) pH 7.4 and then quenched with 30 mM NH4Cl.
Cell permeabilization was performed with Triton for the
Ki-67 staining and with saponin for LAMP 1 and LAMP
2 staining. Alexa-conjugated secondary antibodies were
from Thermo Fisher Scientific. Image deconvolution and
acquisition was performed with an Axio Imager A2M
microscope equipped with an Apotome module (Carl
Zeiss, Jena, Germany).
Immunoblot analysis
BC cells were lysed using lysis buffer (Hepes pH 7.4
20 mM, NaCl 150 mM, 10% Glycerol, 1% Triton X-100)
with protease inhibitors cocktail Complete (Roche Applied
Science, Penzberg, Germany) and sodium orthovanadate
or Phostop (Roche). Proteins were resolved on SDS-
polyacrylamide gel electrophoresis and blotted on nitro-
cellulose (Thermo Fisher Scientific) or PVDF (Merck
Millipore, Darmstadt, Germany) membranes. Detection
was performed with ECL Detection Reagent (GE Health-
care) according to manufacturer’s protocol. ECL signals
were detected, recorded and measured by either the GS-
800 Calibrated Imaging Densitometer and the Quantity
One Software (BioRad, Hercules, CA) or the Li-Cor scan-
ner and Image Studio software (LI-COR Biosciences Inc.,
Lincoln, NE, USA) or the Uvitec Cambridge gel doc
system and software (Cambridge, UK).
Transmission electron microscopy (TEM)
For electron microscopy analysis, SKBR-3 and BT474
cells were seeded on glass chamber slides (Lab-Tek 177,380,
Nalge Nunc int., Rochester, NY, USA) and treated for 7d.
After drug treatments, cells were processed for electron
microscopy [32] and observed with a CM10 electron
microscope (Philips, Eindhoven, The Netherlands). Digital
images were taken with a Megaview 3 camera. Analysis of
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morphologically identified multivesicular bodies (MVBs),
autolysosomes (AL), autophagic vesicle/lipid droplets
(AV/LDs) and lipid droplets (LDs) diameters were
assessed in 10 cells for each treatment. The diameter of
each organelle was measured with iTEM software pack-
age (Olympus-SYS; Olympus Corporation, Shinjuku,
Tokyo, Japan) and plotted as histograms.
RNA extraction and real-time and quantitative PCR (RT qPCR)
RNA was isolated using the Trizol reagent (Thermo
Fisher Scientific), cDNA was synthesized and real-time
quantitative PCR (RT qPCR) was performed in quadru-
plicate using 1 × IQTM SybrGreen SuperMix and CFX
apparatus (Biorad, Milan, Italy). The relative quantity of
target mRNA was calculated by the comparative Cq
method using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as housekeeping gene (GAPDH fwd: 5′-
ACCCACTCCTCCACCTTTGACG-3′; GAPDH Rev. 5′-
CTCTTGTGCTCTTGCTGGGGCTG-3′), and expressed
as fold induction with respect to controls [33]. PLIN2 pri-
mer pairs (PLIN2 Fwd 5′- TGTGAGATGGCAGAGAA
CGGT-3′; PLIN2 Rev. 5′-CTGCTCACGAGCTGCAT
CATC-3′) were designed ad hoc starting from the cod-
ing sequences of Homo sapiens available on the Gen-
Bank database (https://www.ncbi.nlm.nih.gov/genbank/
) and synthesized by Tib MolBiol s.r.l. (Genova, Italy).
PLIN1 primer pairs were purchased from Biorad (# qHsa-
CID0011127). Amplification conditions consisted of 2 min
at 95 °C followed by 5 s at 95 °C and 30 s for PLIN1 or
45 s for PLIN2 at 60 °C for 40 cycles.
Statistical analysis
All measurements here reported are presented as
mean ± standard deviations. For MDA-MB-231 and
MCF7 MTT assay, MDA-MB-231 cell migration assay
and SKBR-3 and BT474 Alamar Blue cell survival
assay we used a two-tailed distribution Student’s t-test.
For ultrastructural studies, we used the Mann–Whitney
test. For BT474 cell migration assay, cell cycle analyses and
Tz-Res SKBR-3 MTTassay, we used one-way ANOVA plus
post-hoc Tukey’s test. For the Ki-67 measurements we used
one-way ANOVA plus post-hoc Bonferroni’s test. For
SKBR-3 and BT474 MTTassays we used two-way ANOVA
plus post-hoc Bonferroni’s test. For SKBR-3 and BT474 RT
qPCR analysis we used one-way ANOVA Kruskal Wallis’s
test plus the post-hoc Tukey’s test. Mean differences were
considered statistically significant (P value) at P < 0.05.
Results
CA inhibits BC cell survival and migration and enhances
Tz in vitro antitumor effects in ERBB2+ BC cells
To establish the in vitro antitumor effects of CA on BC
cells and whether they depend on the expression of
ERBB2, as previously suggested [24], we first analyzed
ERBB2 negative cell lines. In particular, we selected MDA-
MB-231 (estrogen and progesterone receptors negative)
and MFC7 cells (estrogen and progesterone receptors
positive) to study cell survival and migration, two relevant
features associated with aggressiveness and metastatic
potential. Cell viability was assessed by MTT assay up to
10 days (d). We demonstrate that CA at 27.5 μM, a con-
centration that we used previously in GBM cells [23],
significantly decreased the survival of both MDA-MB-231
and MCF7 cells compared to control cells from 6 d of cul-
ture onward (Additional file 2: Figure S2A, B). To assess
the migratory capability of MDA-MB-231 cells upon CA
administration (MCF7 cells were unable to migrate in our
experimental conditions as shown also by others [34]), we
performed a transwell migration assay and found that CA
drastically inhibited the migration of these cells compared
to controls (Additional file 2: Figure S2C). Subsequently,
we investigated the effects of CA in two ERBB2+ BC cell
lines, the SKBR-3 (estrogen and progesterone receptors
negative) and the BT474 cells (estrogen and progesterone
receptors positive). In particular, we wondered whether
CA could cooperate with Tz, a therapeutic antibody di-
rected to ERBB2, to enhance the in vitro antitumor activ-
ities of this drug. To mimic a chronic drug administration,
we first determined the concentrations of CA able to in-
hibit cell survival at 50% of the control in 7d of culture.
These were 27.5 and 37.5 μM for CA in SKBR-3 and
BT474, respectively (data not shown). Similarly, we deter-
mined the Tz concentration inhibiting cell survival at 50%
of the control in 7d of culture. These were 10 μg/ml and
0.24 μg/ml in SKBR-3 and BT474, respectively (data not
shown). All subsequent experiments were performed with
these CA and Tz concentrations.
We then performed the MTT assay up to 10 d to
evaluate SKBR-3 and BT474 cell survival under CA, Tz
and the combined treatment. As shown in Fig. 1, both
CA and Tz significantly reduced BC cell survival in both
cell lines from 6d onward (P < 0.01 at 6d, Ctr vs CA or
Tz). Notably, the combined treatment strongly enhanced
this reduction (P < 0.001 at 6d, Ctr vs CA + Tz, CA or
Tz vs CA + Tz), suggesting a cooperative antitumor ef-
fect of the two drugs. To test whether the anti-survival
effect of CA + Tz treatment was permanent or transient,
we cultured SKBR-3 and BT474 cells with CA + Tz for
14 days. In parallel, we co-treated cells with CA + Tz for
6 d, then these cells were washed out and replaced with
fresh control medium for additional 8 d. Cell survival
analyses unveiled that both SKBR-3 and BT474 BC cells
restarted proliferating when cultured in control medium,
suggesting that the growth inhibitory effect was reversible
(Additional file 3: Figure S3). We previously reported that
CA inhibits the survival of both GBM cells and normal
astrocytes [32]. To assess whether CA is effective in the
inhibition of survival of a widely used normal mammary
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epithelial cell model and cooperates in that with Tz, we
used the MCF10A cells [35, 36]. In particular, we treated
these cells for 7d with the maximal concentration of CA
and Tz used for the ERBB2+ cancer cell lines (37.5 μM CA
and 10 μg/ml Tz, respectively) and performed the MTT
assay. Our results showed, as expected, that CA inhibited
MCF10A cell survival whereas Tz had no major effect on
these cells (Additional file 4: Figure S4A).
As for MDA-MB-231 cells, we analyzed the migratory
ability of the BT474 cells (SKBR-3 cells were unable to
migrate in our settings as shown also by others [34], data
not shown). We demonstrated a statistically significant
reduction of cell migration under CA or Tz when used
as single treatment (Fig. 2a-b). Remarkably, the combined
treatment potentiated the inhibition of cell migration.
CA in combination with Tz induces cell cycle arrest in G0/
G1 and reduces the ERBB2+ BC cells fraction in G2/M
CA-mediated apoptosis was described in prostate cancer
cells by modulation of the AKT/IKK/NF-KB pathway
[22]; however, only a moderate early apoptosis was de-
tected in human GBM cells [23]. To investigate whether
the reduction of cell survival upon CA and Tz adminis-
tration in ERBB2+ cells was due to activation of the
apoptotic program, we treated SKBR-3 and BT474 with
CA, Tz and in combination for 48 h. Cells were then an-
alyzed by a FCM apoptosis assay, which allowed the
identification of early apoptotic, late apoptotic and nec-
rotic cells (Additional file 5: Figure S5A). This analysis
showed that CA, Tz and the combined treatment did
not induce early/late apoptosis or necrosis. To confirm
this result after a prolonged exposure to drug treat-
ments, we performed western blot analysis at 7d for the
cleaved Caspase-9, a well-known apoptotic marker. As
shown in Additional file 5: Figure S5B, we could not
show major modulation of cleaved Caspase-9 levels in
treated samples compared to controls in both cell lines,
ruling out apoptosis as a relevant cause of survival inhib-
ition in our experimental conditions.
As we previously showed that CA induced cell cycle
arrest in GBM cell [23], we examined whether CA inhib-
ited cell cycle progression also in SKBR-3 and BT474
cells. Both cell lines were treated with CA, Tz and co-
treated with CA + Tz for 48 h. The DNA content was
evaluated by high resolution (hr) DNA-FCM (Fig. 3a)
and representative DNA content histograms are shown
in Additional file 6: Figure S6. This analysis showed that
Tz-treated SKBR-3 and BT474 cultures accumulated
cells in the G0/G1 phase of the cell cycle along with a
reduction of cells in the G2/M phase compared to un-
treated cells. A statistically significantly increase of cells in
the G0/G1 phase as well as a consistent decrease of CA
and CA + Tz treated cells in the S phase was observed
only in BT474 cells (Fig. 3a). Of note, in both cell types
the co-treatment with CA + Tz increased the amount of
cells in G0/G1 phase of the cell cycle with respect to sin-
gle drug treatments, suggesting that CA cooperates with
Tz in inducing a G0/G1 cell cycle arrest and in the reduc-
tion of the cell fraction in G2/M phase (Fig. 3a).
To clarify whether CA and Tz arrested cells in the G0
or in the G1 cell cycle phase, we further investigated the
levels of the cell proliferation marker Ki-67, which only
labels cells engaged in the cell cycle [37], upon CA, Tz
or the combination CA + Tz in BT474 and SKBR-3 cells
cultured for 7d (Additional file 7: Figure S7). Immuno-
fluorescence analysis showed low-levels of Ki-67 expres-
sion in BT474 cells treated with CA, Tz and the
combined treatment. At difference, SKBR-3 cells showed
Fig. 1 CA and Tz cooperatively inhibit SKBR-3 and BT474 in vitro cell survival. Cells were cultured for 10d with control medium (Ctrl), CA, Tz or
CA + Tz supplemented medium, which was changed every 48 h. Cell survival is expressed as arbitrary units (A.U.) after exposure of MTT agent for
4 h. Exponential (Expon.) or polynomial (Poly.) interpolation curves are shown. Mean values and standard deviation (indicated as vertical bars)
from three independent replicates (n = 3) are shown. Asterisks indicate statistical significativity P < 0.001 (***) of Ctr vs CA, Ctr vs Tz and Ctr vs
CA + Tz. ### indicate statistical significativity P < 0.001 (###) of CA and Tz vs CA + Tz
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a significant decrease of Ki-67 only in Tz or CA + Tz
treated cells (Additional file 7: Figure S7). Collectively,
these data suggest that CA + Tz cells were mainly
arrested in the G0 phase and exited the cell cycle before
the accomplishment of the G1 phase [37].
CA and Tz treatments do not cooperate in inducing
endoplasmic reticulum and ROS stress in ERBB2+ BC cells
As in other cell types the mechanism of action of CA
involves endoplasmic reticulum stress and ROS produc-
tion [18], we investigated by immunoblot analysis the
levels of HSP70 and Calreticulin, used as endoplasmic
reticulum stress markers and Catalase, which is a ROS
stress marker, in both BT474 and SKBR-3 cells treated
with CA and Tz for 7d. This analysis, showed that CA
and Tz modulates in a slightly different manner these
stress markers in both cell types (Additional file 8:
Figure S8). While Calreticulin was slightly induced by
CA In SKBR-3, HSP70 levels showed a reduction upon
CA, Tz and the combined treatment, compared to con-
trols (Additional file 8: Figure S8). Finally, Catalase levels
did not show major changes with both drugs, alone or in
combination (Additional file 8: Figure S8). At variance, in
BT474 cells both calreticulin and HSP70 showed an incre-
ment in CA and in CA + Tz treated cells compared to
controls, while Catalase was induced by all treatments
(Additional file 8: Figure S8). However, we did not find a
cooperative CA and TZ inducing effect on the levels of
these stress markers (Additional file 8: Figure S8).
CA and Tz treatments inhibit the ERBB2 signaling
pathway and cooperatively upregulate CDKN1B/p27KIP1
expression levels
It is well known that Tz inhibits ERBB2 downstream sig-
naling pathways modulating AKT and MAPK signaling
cascades [2, 38] and down-regulates ERBB2 expression
[5, 39]. Reduced downstream signaling through these
pathways activates p27KIP1 leading to G1 cell cycle arrest
Fig. 2 CA and Tz cooperatively inhibit in vitro BT474 cell migration. Cells were cultured after 48 h of starvation for 7d with control medium (Ctr),
CA, Tz or CA + Tz supplemented medium in the lower migration chamber, which was changed every other day. a Representative images of the
lower side of the migration membranes stained with Crystal Violet. Bar = 100 μm. b Relative cell migration expressed as percentage (%)
compared to Ctr cultures was determined as detailed in Methods section. Mean values and standard deviation (indicated as vertical bars) from
four independent replicates (n = 4) are shown. P < 0.005 (*), P < 0.01 (**), P < 0.001 (***)
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[40, 41]. Therefore, to investigate the mechanism/s
through which CA and CA + Tz induce G0/G1 cell cycle
arrest, we examined by immunoblot analysis ERBB2 pro-
tein levels and the phosphorylation status of AKT (after
7d of culture). This analysis showed that in SKBR-3 cells,
ERBB2 levels were similarly reduced upon single or
combined treatments (Fig. 3b). Notably, in BT474 cells,
while the level of ERBB2 was only slightly down-regulated
upon single treatments, the combination of both drugs in-
duced a strong decrease of the receptor levels (Fig. 3b).
The evaluation of ERBB2 downstream signaling revealed
dephosphorylation of AKT Serine 473 upon single
and combined treatments in both cell lines after 7d
of culture (Fig. 3b).
We next evaluated the levels of two key regulators of
the G1 cell cycle phase, CDKN1A/p21WAF1 and
CDKN1B/p27KIP1 by immunoblot analysis. The results
unveiled a strong activation of p27KIP1 upon single treat-
ment and a synergic inducing effect upon combined
treatment in both cell lines (Fig. 4a). A robust up-
regulation of protein levels was also observed for
p21WAF1 in CA, Tz and CA + Tz treated SKBR-3 and
Fig. 3 CA and Tz cooperatively arrest cell cycle in G0/G1 and down-regulate ERBB2 levels and signaling in SKBR-3 and BT474 cells. a High resolution
DNA flow cytometric analysis of DAPI-stained nuclei of cells cultured for 48 h with control medium (Ctr), CA, Tz or CA + Tz supplemented medium.
Both floating and adherent cells were collected for the analysis. Mean values and standard deviation (indicated as vertical bars) from four independent
replicates (n = 4) are shown. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***). b Cells were cultured for 7d with control medium (Ctr), CA, Tz or
CA + Tz supplemented medium, which was changed every other day. A representative immunoblot analysis is shown, which was performed with
anti-ERBB2, anti phospho-Ser473 AKT, anti AKT, anti-Tubulin and anti-Vinculin antibodies on whole cell lysates. Tubulin is shown as loading control for
ERBB2. Vinculin is shown as loading control for pAKT and AKT. Numbers on each lane represent ERBB2 protein levels and pAKT/AKT level
ratios determined as described in Methods
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BT474 cells (Additional file 9: Figure S9). However, we
could not detect a cooperative induction in the combined
treatment (Additional file 9: Figure S9). As p27KIP1 is
functional as a cyclin-dependent kinases (CDKs) inhibitor
only when is located in the nucleus [42], we investigated
its subcellular localization through immunofluorescence
analysis in BT474 and SKBR-3 cells treated for 7d with
CA + Tz. This analysis showed the presence of the protein
p27KIP1 in the nuclei of CA + Tz ERBB2+ treated cancer
cells (Fig. 4b). To establish whether CA induces CDK pro-
tein inhibitors in MCF10A cells we performed immuno-
blot analysis with p27KIP1 and p21WAF1 specific antibodies.
We showed that, after 7d of drug treatments, CA dramat-
ically increased the protein levels of the latter whereas re-
duced the former. On the contrary, a 7d treatment with
Tz only slightly increased the levels of p27KIP1 with no
major effect on those of p21WAF1 in these cells (Additional
file 4: Figure S4B).
CA inhibits late autophagy in ERBB2+ BC cells
Activation of autophagy in BC cells is a challenge re-
garding therapeutic resistance [15]. In this study, we
assessed whether CA and Tz modulated autophagy in
our cell model systems after 7d of exposure to treat-
ments. To monitor the autophagy process, we evaluated
both ATG5 and LC3 I/II levels by immunoblotting as
functional reporters in SKBR-3 and BT474 cells treated
with CA, Tz and CA + Tz for 7d (Fig. 5). Immunoblot
results indicated that Tz led to increase of the LC3 II/I
ratio and ATG5 down-regulation in both cell types.
Similarly, CA caused an increase of the LC3 II/I ratio in
both cell types whereas it did not modify ATG5 levels
compared to controls. The combined treatment with CA
and Tz appeared to be substantially in line with the ef-
fects of both drugs used as single treatments for what
concerns the LC3 II/I ratio. With regards to ATG5
levels, the effects of CA + Tz were similar to those
detected with the use of Tz alone (Fig. 5). As both the
induction and suppression of autophagosome maturation
may result in accumulation of LC3 II, to distinguish
whether LC3 II accumulation was caused by autophagyFig. 4 CA and Tz cooperatively upregulate p27
KIP1 expression levels
in SKBR-3 and BT474 cells. Cells were cultured for 7d with control
medium (Ctr), CA, Tz or CA + Tz supplemented medium, which was
changed every other day. a A representative immunoblot analysis is
shown, which was performed with anti-p27KIP1 antibody on whole
cell lysates. Tubulin is shown as loading control. Numbers on each
lane represent p27KIP1 protein levels determined as described in
Methods. b Epifluorescence images of SKBR-3 and BT474 cells
cultured for 7d with CA + Tz fixed, permeabilized and challenged
with anti p27KIP1 antibody and Alexa488-conjugated anti-mouse or
with Alexa488-conjugated anti-mouse only as negative secondary
antibody control (green signal). Nuclei were stained with DAPI (red
signal). The extent of overlap is shown in yellow in the merged
images (rightmost column) and arrowheads indicate some cells
displaying p27KIP1 nuclear localization. Bar = 20 μm
Fig. 5 CA upregulates p62 in SKBR-3 and BT474 cells. Cells were
cultured for 7d with control medium (Ctr), CA, Tz or CA + Tz
supplemented medium, which was changed every other day. A
representative immunoblot analysis is shown, which was performed
with antibodies specific for p62, ATG5, LC3 and Vinculin on whole
cell lysates. Vinculin is shown as loading controls. Numbers on each
lane represent p62 and ATG5 levels and LC3 II/I level ratios, determined
as described in Methods
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induction or by inhibition of downstream steps, we used
SQSTM1/p62 as a marker to measure the autophagic
degradation activity [43]. The p62 protein specifically
interacts with LC3 for its degradation by autophagolyso-
somes [43]. In fact, p62 accumulates when late autophagy
is inhibited, and decreased levels can be observed when
autophagy is induced [43]. We show that CA and the
combined treatments CA + Tz induced accumulation of
p62 in both SKBR-3 and BT474 cells, while Tz did not
(Fig. 5). Interestingly, when we performed an immunoblot
assay with the p62 antibody on MCF10A cells extracts, we
detected higher levels of this protein in CA treated but
not in Tz treated cells (Additional file 4: Figure S4B). The
increase of LC3 II levels in ERBB2+ BC cells together with
the increase of p62 suggests that CA is impairing the
autophagic flux blocking a late maturation step of autop-
hagosome degradation, i.e. the fusion to the lysosome or
the lysosomal digestion.
To better visualize cellular structures accumulated after
7d of CA, Tz and CA + Tz treatments, we performed TEM
analysis in SKBR-3 cells. We quantified 4 categories of
structures based on morphological criteria, the multivesicu-
lar bodies (MVB), autophagic vesicles (AV), autolysosomes
(AL) and lipid droplets-derived autophagic vesicles (AV/
LD). Interestingly, we found that CA induced a marked
accumulation of MVB and enlarged AL, as well as lipid
mobilization through the formation of aberrant AV/LD
(Fig. 6a-c). These AV/LD structures often appear bi-phasic,
with a low-density core surrounded by a more homoge-
neous dense lipid layer and by multilamellar tightly packed
electron-dense membranes (Fig. 6a). In contrast, Tz-treated
cells showed a decrease of AV and AL compared to CA-
treated cells and very few AV/LD. Similarly to CA-treated
cells, accumulation of AV/LD was observed in cells co-
treated with CA + Tz, while the number of AL and MVBs
was comparable to Tz-treated cells (Fig. 6b). Taken to-
gether, TEM analysis indicates that CA induces a late stage
inhibition of autophagy by accumulating AL and aberrant
AV/LD.
Lysosomal protein degradation constitutes the final
step of autophagy [44]. Accumulation of AL and AV/LD
mediated by CA would reflect dramatic changes in the
lysosomal compartment. We therefore assessed whether
CA and CA + Tz affects the morphology of lysosomes
as a result of the inhibition of the autophagic flux.
LAMP1 and LAMP2, two glycoproteins abundantly
expressed on the lysosomal membrane, are commonly
used markers of lysosomes. Indeed, in SKBR-3 cells
treated with CA and CA + Tz for 7d, the LAMP1 posi-
tive structures decreased but their size increased (Fig. 7),
demonstrating that CA strongly impacts on lysosomal
morphology. Accordingly, CA-induced alterations of the
lysosomal compartment were also observed in MCF10A
cells (Additional file 4: Figure S4C).
Previous reports showed that Tz induces lipid accumula-
tion and differentiation in ERBB2+ BC cells [45]. To verify
whether adipogenesis and/or differentiation were mod-
ulated by exposures to CA, Tz and to the combined
treatment, we assessed by RT qPCR the transcription of
Perilipin 1 (PLIN1) for adipogenesis and Perilipin 2
(PLIN2) for differentiation, two major genes that regu-
late lipid homeostasis in SKBR-3 and BT474 cells [46].
In addition, we also assessed the levels of PPARγ, the
master regulator of adipocyte differentiation, by immu-
noblot analysis. We report that Tz, as well as CA + Tz
induced a significant increase in PLIN1 mRNA levels in
SKBR-3 cells while in BT474 PLIN1 mRNA levels were
increased only by Tz (Additional file 10: Figure S10A).
In contrast, CA did not up-regulated PLIN1 mRNA
levels in both cell types. A significant up-regulation of
PLIN2 expression levels was observed only in CA
treated compared to Tz and CA + Tz treated SKBR-3
cells (Additional file 10: Figure S10A). Moreover, we
did not observe modulation of PPARγ protein levels in
SKBR-3 cells (Additional file 10: Figure S10B). Taken
together, SKBR-3 cells appear more sensitive to CA-
induced lipid mobilization compared to BT474 cells.
CA partially restores Tz sensitivity in Tz-resistant
SKBR-3 cells
Primary or acquired resistance to Tz is still a major clinical
problem for BC patients [5]. Indeed, to optimize drug
response, Tz is usually used in combination with chemo-
therapeutic agents [5]. In this respect, we wondered
whether CA could be active as anti-survival agent and
rescue Tz response in Tz-resistant ERBB2+ BC cells. To
test this hypothesis, we used SKBR-3 resistant cells (Tz-
Res SKBR-3) able to growth in 200 μg/ml Tz, and deter-
mined cell survival through MTT assay. As for parental
Tz-sensitive SKBR-3 cells, Tz-Res SKBR-3 cells were
treated with CA (27.5 μM), Tz (10 μg/ml) or Tz + CA and
after 7d of treatment, cell survival was measured (Fig. 8a).
As expected, this analysis revealed that these cells were
unresponsive to Tz but sensitive to CA. Remarkably, Tz-
Res SKBR-3 cells treated with the combination Tz + CA
showed a statistically significantly lower survival com-
pared to that of cells treated with CA alone (Fig. 8a). To
shed light on the mechanism through which Tz-Res
SKBR-3 cells partially restored Tz sensitivity, we decided
to examine the ERBB2 signaling pathway. Tz-Res SKBR-3
cells were treated with CA, Tz or CA + Tz for 7 d. Immu-
noblot analysis revealed that ERBB2 protein levels were
decreased upon CA treatment and even more in CA + Tz
treated cells whereas, as expected, ERBB2 levels were
unchanged in cells treated with Tz alone (Fig. 8b). Con-
cerning the ERBB2 downstream signaling, we observed in
Tz-Res SKBR-3 a dramatic dephosphorylation of AKT
Serine 473 upon CA and the combined treatment, while
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only a minor dephosphorylation was observed in cells
treated with Tz alone (Fig. 8b). Interestingly, when we in-
vestigated the expression of p62 in Tz-Res SKBR-3, we ob-
served that CA alone or in combination with Tz induced a
dramatic up-regulation of p62 levels compared to Tz or
controls (Fig. 8b).
Discussion
The identification and characterization of the anticancer
properties of natural products have aroused significant
interest over the years. Several studies have shown that
CA has antitumor properties in several cancer cell
models [18]. However, a comprehensive evaluation of
Fig. 6 CA impairs autophagic flux accumulating autolysosomes (AL) and aberrant autophagic vesicles/lipid droplets (AV/LDs). a Representative
TEM images of SKBR-3 and BT474 cells untreated (Ctr), CA-treated (+CA), Tz and CA + Tz treated for 7d. Four major categories of structures could be
distinguished by morphological criteria in CA-treated cells: multivesicular bodies (MVBs), autolysosomes (AL) autophagic vesicle/lipid droplets (AV/LDs)
and lipid droplets (LDs). Nuclei (N), Golgi (G), mitochondria (mit). Bar = 700 nm. b-c Histograms showing the number and diameter of each endocytic/
autophagic structures upon different treatments in SKBR-3 cells. For this analysis, 10 whole cells were scored and measured for each category of
structures with iTEM imaging software. Note that in CA-treated cells the most represented category is AV/LDs, followed by AL and MVBs
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CA as anticancer agent in ERBB2+ BC cells is still lack-
ing. For this reason, in this study we aimed at verifying
whether CA was active in BC cells and specifically
whether it could enhance the in vitro antitumor effects
of Tz in ERBB2+ cells.
Differently from previous reports [24], our findings
show that CA inhibits cell survival and migration in
both ERBB2− and ERBB2+ BC cells and, therefore, that
its function is independent from the expression of this
receptor. In addition, we have found that CA and Tz co-
operate in inhibiting both migration and survival in
ERBB2+ BC cells.
One of the major effects of both CA and Tz is to in-
hibit cell cycle progression [23, 47, 48]. Therefore, we
have investigated cell distribution in cell cycle phases
and demonstrated that the combined treatment with
these two agents was more effective in blocking ERBB2+
BC cells in G0/G1 compared to CA and Tz alone. Ac-
cordingly, the decrease of Ki-67 expression, a cell prolif-
eration marker, further showed that in ERBB2+ BC cells
the block observed upon the Tz and CA + Tz treatments
occurs mainly in G0. Noteworthy, others studies and
ours have shown that CA causes a late G2 [23] or a G2/
M block [47] in other cancer cell types. Thus, it appears
that CA effects on cell cycle are cell context dependent.
In ERBB2+ BC cells, our data strongly suggest that the
cooperative mechanism exploited by CA and Tz causes
cell cycle arrest in G0, which involves the induction of
p27KIP1, as both drugs also cooperatively increase the
levels of this CDKs inhibitor. According to this result,
the observation of nuclear localization of p27KIP1 in
ERBB2+ BC cells treated with CA + Tz is consistent with
Fig. 7 CA and CA + Tz dramatically affect lysosomal morphology in SKBR-3 cells. Representative confocal images of SKBR-3 cells cultured for 7d
with CA, Tz and CA + Tz and untreated cells. Cells were fixed, permeabilized and challenged with anti-LAMP1 and anti-LAMP2 antibodies to
detect lysosomes and Alexa488-conjugated anti-mouse secondary antibody (green signal). Nuclei were stained with DAPI (blue signal). Arrows
indicates representative lysosomes in each condition. Of note, in CA and CA + Tz treated cells lysosomes (LAMP1 and LAMP2 positive) appear
larger and clustered with respect to untreated cells (arrows). Bar = 20 μm. Insets represent a detail of the original image
D’Alesio et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:154 Page 11 of 16
this proposed mechanism. However, we cannot rule out
that the concomitant induction of p21WAF1, which we
have also observed in GBM cells [23], may contribute,
albeit to a lesser extent, to the cell cycle arrest deter-
mined by the CA + Tz treatment in these cells.
The chains of molecular events activated or repressed
by CA and Tz, upstream to the induction of CDK inhibi-
tors, remain unclear. In particular, we point to the evi-
dence that although both ERBB2 expression levels and
AKT phosphorylation levels were reduced by both drugs
when used individually, we have not found a consistent
combined effect on ERBB2 and AKT phosphorylation in
both ERBB2+ BC cell lines. For example, CA and Tz
cooperatively reduced ERBB2 levels in BT474 (estrogen
receptor positive, ER+) but not in SKBR-3 (estrogen re-
ceptor negative, ER−) cells. As ER− status correlates with
ERBB2 overexpression and poorly differentiated tumors
[49], further studies are needed to determine if CA
preferentially targets ER+ versus ER− BC cells, therefore
providing a conceivable explanation for the differences
observed in the two ERBB2+ cell lines.
Cancer cells tend to activate autophagy for their sur-
vival. Here we have reported for the first time that CA
inhibits autophagy by impairing the autophagic flux in a
peculiar way that may impact cell survival of cells also
exposed to Tz. Importantly, we demonstrate that CA
does not affect ATG5, an E3 ubiquitin ligase necessary
for the early stages of autophagosome formation, but
that it increases p62 and LC3 II levels. These events
likely lead to the accumulation of AL and aberrant AV/
LD structures in ERBB2+ BC cells. In addition, we show
that p62 induction by CA is more evident in SKBR-3
Tz-Res than in parental Tz-sensitive SKBR-3. Overall,
our data demonstrate that CA disrupts the autophagic
flux, thus impairing an important cancer survival path-
way, which is also relevant in resistance to Tz. Notably,
Fig. 8 CA and Tz cooperatively inhibit in vitro survival of Tz-resistant SKBR-3 cells. a Cells were cultured for 7d with control medium (Ctr), CA, Tz
or CA + Tz supplemented medium, which was changed every 48 h. Cell survival is expressed as arbitrary units (A.U.) after exposure of cultures to
MTT for 4 h. Mean values and standard deviation (indicated as vertical bars) from three independent replicates (n = 3) are shown. P < 0.05 (*),
P < 0.01 (**), P < 0.001 (***). b Cells were cultured for 7d with control medium (Ctr), CA, Tz or CA + Tz supplemented medium, which was changed
every 48 h. A representative immunoblot analysis is shown, which was performed with anti-ERBB2, anti phospho-Ser473 AKT, anti AKT, anti p62,
anti-Tubulin and anti-Vinculin antibodies on whole cell lysates. Tubulin is shown as loading controls for ERBB2. Vinculin is shown as loading
controls for pAKT, AKT and p62. Numbers on each lane represent ERBB2 levels, pAKT/AKT ratios, and p62 levels determined as described in
Methods. c Working model of CA and Tz effects in ERBB2+ breast cancer cells and proposed mechanisms of action
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our data showing induction of p62 not only in ERBB2+
BC cells but also in MCF10A cells, strongly suggest that
CA is a general inhibitor of autophagy.
Furthermore, we have shown that in Tz-resistant
SKBR-3 cells CA and Tz cooperate in reducing ERBB2
levels along with a dramatic AKT dephosphorylation.
Most importantly, we have proven a statistically signifi-
cantly decrease of cell survival in Tz-resistant cells treated
with CA + Tz compared to CA alone. This observation
implies a partial rescue of the Tz action. It is tempting to
speculate that the derangement of the endocytic/lyso-
somal pathway caused by the CA may impair the recycle
of the ERBB2 to the plasma membrane. Certainly, further
studies are needed to clarify the molecular mechanism
responsible for the observed rescue of Tz activity.
As obstruction of the autophagic flux might lead to
endoplasmic reticulum stress and, ultimately, apoptosis,
we have consequently investigated apoptosis, necrosis,
endoplasmic reticulum stress and ROS production as
possible cellular processes that could impair cell survival
in our ERBB2+ BC cell models (SKBR-3 and BT474).
Though none of these processes were reported to have a
major role in the Tz mechanism of action, several studies
have highlighted their involvement in CA-induced inhib-
ition of cell survival in cancer cell lines [18]. In our experi-
mental context, CA and Tz, alone or in combination, have
not elicited significant cell apoptosis or necrosis. However,
the involvement of endoplasmic reticulum and ROS stress
is less clear, since we have not found a consistent modula-
tion of the HSP70 chaperone, calreticulin and catalase
markers in the two ERBB2+ BC cell lines. Indeed, although
CA and Tz up-regulated calreticulin, alone or in combin-
ation in both cell types, HSP70, which is also an endoplas-
mic reticulum stress marker, was up-regulated in BT474
but down-regulated in SKBR-3 cells.
Finally, we have evaluated whether an aberrant differ-
entiation process could contribute to cell cycle arrest
and survival inhibition in ERBB2+ BC cells treated with
CA and Tz. An increase of neutral lipid production, as-
sociated with cell differentiation, was indeed reported to
occur in SKBR-3 and in BT474 cells treated with Tz
[45]. On the other hand, contrasting data exist on CA-
mediated modulation of PPARγ, which is a key transcrip-
tion factor up-regulated during adipogenesis [50, 51]. In
this study, we have evaluated PPARγ protein levels, which
is a major pro-adipogenic transcription factor [52], and
the mRNA levels of PLIN1 and PLIN2, two proteins asso-
ciated to the coat of lipid droplets that block lipolysis and
increase during lipid accumulation [53–56], respectively.
As we have observed that PPARγ levels were unchanged
in SKBR-3 and that PLIN1 and PLIN2 mRNA levels were
not modified consistently in the two ERBB2+ BC cells co-
treated with CA and Tz, we conclude that the activation
of an aberrant differentiation process, possibly activated
by CA and Tz, is unlikely to have a major role in cell cycle
arrest caused by CA and Tz in our experimental context.
Finally, we would point that CA inhibition of cell survival,
the induction of both p21WAF1 and p62 and derangement
of the endocytic/lysosomal pathway have been observed
both in BC cells and in normal mammary epithelial cells. It
should be noticed, however, that MCF10A cells are spon-
taneously immortalized mammary epithelial cells [35] with
a doubling time that is actually shorter (16 h) [57] than that
of the SKBR-3 and BT474 cells (44 and 72 h, respectively)
[58, 59]. Therefore, it is very likely that MCF10A cells have
a deranged control of the cell cycle perhaps explaining why
we have observed p21WAF1 but not p27KIP1 induction medi-
ated by CA.
Survival analysis in MCF10A treated with CA confirms
and extends our previous observation in normal human
astrocytes [32] and appears to limit a putative in vivo
use of CA for cancer treatment. However, the cooperative
activities of CA with Tz in ERBB2+ BC cells and the obser-
vation that 90 d administration of rosemary extract (equiva-
lent to 20–60 mg/Kg/d of carnosol plus CA) in rats
revealed no adverse effects [17] warrant further studies
on the possible therapeutic use of CA in ERBB2+ BCs.
Currently, the attempt to block the cellular survival
functions of autophagy in cancer by combining chemo-
therapy with the autophagy inhibitor cloroquine and/or
hydroxychloroquine is undergoing promising clinical trials
in several aggressive tumors [16]. Yet, a possible alternative
strategy in fighting resistance or boosting the anticancer
activity of specific antibodies is to couple the targeting
of ERBB2 with phytochemical compounds with low
toxicity profiles, such as CA [17], which may interfere
with therapy-induced protective autophagy as standa-
lone drugs.
Conclusions
Our study shows for the first time that CA and Tz co-
operate in inhibiting BC cell migration and survival. This
latter inhibitory effect, which occurs in both Tz-sensitive
and Tz-resistant cells, results from multiple mechanisms
that ultimately cause cell cycle arrest and inhibition of
the late stages of the autophagic flux (Fig. 8c). Given the
increasing efforts to find pharmacologically safe natural
compounds with anticancer properties, our results war-
rant further in vivo studies to establish the full potential
of CA or CA analogues as adjuvant drugs in the treat-
ment of ERBB2+ cancers.
Additional files
Additional file 1: Table S1. Antibodies used for immunoblot analysis.
(DOCX 78 kb)
Additional file 2: Figure S2. CA inhibits ERBB2− in vitro breast cancer
cell survival and migration. MCF7 and MDA-MB-231 cells were cultured
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for 10 days with control medium (Ctr), CA, Tz or CA + Tz supplemented
medium, which was changed every 48 h. a Cell survival is expressed as
arbitrary units (A.U.) after exposure to MTT agent for 4 h. Polynomial
(Poly.) interpolation curves are shown. Mean values and standard deviation
(indicated as vertical bars) from three independent replicates are shown. b
MDA-MB-231 cells were cultured after overnight starvation for 7d with
control medium (Ctr) or CA supplemented medium in the lower migration
chamber, which was changed every 48 h. Representative images of the
lower side of the migration membranes stained with Crystal Violet.
Bar = 100 μm. c Relative cell migration expressed as percentage (%)
compared to control was determined as detailed in Methods section. Mean
values and standard deviation (indicated as vertical bars) from four independent
replicates (n = 4) are shown. P < 0.001 (***) (TIFF 10150 kb)
Additional file 3: Figure S3. CA and Tz cooperative inhibition of ERBB2
+ cell survival is transient. Blue lines represent cell survival of SKBR-3 and
BT474 cells continuously cultured with CA + Tz (cultures #2). Red lines
represent cell survival of SKBR-3 and BT474 cells cultured for up to 6d
with CA + Tz and for further 8d with control medium (cultures #1). Cell
survival is expressed as arbitrary units (A.U.) after exposure of cultures to
Alamar Blue for 4 h. The arrow represents the time point at which the
medium containing the two drugs was replaced with control medium in
cultures #1. Mean values and standard deviation (indicated as vertical
bars) from four independent replicates (n = 4) are shown. P < 0.001 (***)
(TIFF 817 kb)
Additional file 4: Figure S4. CA impairs survival, increases P21WAF1 and
p62 expression levels and deranges the lysosomal compartment of
MCF10A cells. Cells were cultured for 7d with control medium (Ctr), CA,
Tz or CA + Tz supplemented medium, which was changed every 48 h.
(A) Cell survival is expressed as arbitrary units (A.U.) after exposure to MTT
agent for 4 h. Mean values and standard deviation (indicated as vertical
bars) from three independent replicates (n = 3) are shown. P < 0.05 (*),
P < 0.01 (**), P < 0.001 (***). (B) A representative immunoblot analysis is
shown, which was performed with antibodies specific for P27KIP1,
P21WAF1, p62 and Tubulin on whole cell lysates. Tubulin is shown as
loading controls. Numbers on each lane represent protein levels
determined as described in Methods. (C) Representative confocal images
of SKBR-3 cells cultured for 7d with CA, Tz and CA + Tz and untreated
cells. Cells were fixed, permeabilized and challenged with anti-LAMP1
and anti-LAMP2 antibodies to detect lysosomes and Alexa488-conjugated
anti-mouse secondary antibody (green signal). Nuclei were stained with
DAPI (blue signal). Arrows indicates representative lysosomes in each
condition. Of note, in CA and CA + Tz treated cells lysosomes (LAMP1
and LAMP2 positive) appear larger and clustered compared to untreated
cells (arrows). Bar = 20 μm (TIFF 4806 kb)
Additional file 5: Figure S5. CA and Tz alone or together do not
modify substantially the extent of apoptosis or necrosis in ERBB2+ cells.
A) FCM analysis of SKBR-3 and BT474 cells after 48 h of exposure to CA or
DMSO. Cells were labeled with sytox blue, allophycocyanin (APC)-conjugated
annexin V and resorufin. Both floating and adherent cells were collected for
the analysis. The percentage of early apoptotic cells (sytox blue
negative, APC-annexin V positive, and resazurine positive), late apoptotic
cells (sytox blue positive, APC-annexin V positive) and necrotic cells (sytox
blue positive, APC-annexin V negative, and resazurine negative) is shown.
Mean values and standard deviation (indicated as vertical bars) from three
independent experiments are shown. B) Immunoblot analysis of activated
Caspase-9 (Act. Caspase 9) and Tubulin, which is shown as a loading control,
in SKBR-3 and BT474 treated with CA and Tz. (TIFF 560 kb)
Additional file 6: Figure S6. Representative DNA content histograms
obtained by high resolution DNA flow cytometry from SKBR-3 and BT474
cells, top and bottom row respectively. X axes show DNA content measured
as intensity of fluorescent light emitted by DNA bound DAPI at 435 nm; Y
axes show number of nuclei (counts). Arrow heads indicate G0/G1 and G2/
M peaks. Control treatment, Ctr; Carnosic acid treatment; CA; Trastuzumab
treatment, Tz; Carnosic plus Trastuzumab treatment, CA + Tz. (TIFF 396 kb)
Additional file 7: Figure S7. Ki-67 expression modulation by CA and
Tz. Cells were cultured for 7d with control medium (Ctr), CA, Tz or
CA + Tz supplemented medium, which was changed every 48 h. Cells
were fixed and permeabilized and Ki-67 was detected by indirect immuno-
fluorescence analysis using a mouse anti-Ki-67 antibody (see Additional file 1:
Table S1) and Alexa488-conjugated goat anti-mouse antibodies. Nuclei were
stained with DAPI. Ki-67 positive nuclei and total nuclei were counted in
blind. Four microscopic fields (n = 4) were analyzed for each experimental
condition. Mean values and standard deviation (indicated as vertical bars)
are shown. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***). (TIFF 229 kb)
Additional file 8: Figure S8. Analysis of endoplasmic reticulum and
ROS stress markers expression. Cells were cultured for 7d with control
medium (Ctr), CA, Tz or CA + Tz supplemented medium, which was
changed every 48 h. A representative immunoblot analysis is shown,
which was performed with anti-HSP70, anti-Catalase and anti-Calreticulin
antibodies on whole cell lysates. Tubulin and Actin are shown as loading
controls. Numbers on each lane represent protein levels determined as
described in Methods. (TIFF 200 kb)
Additional file 9: Figure S9. CA and Tz up-regulate p21WAF1 expression
levels in SKBR-3 and BT474 cells. Cells were cultured for 7d with control
medium (Ctr), CA, Tz or CA + Tz supplemented medium, which was changed
every 48 h. A representative immunoblot analysis is shown, which was
performed with an anti-p21WAF1 antibody on whole cell lysates. Tubulin
is shown as loading control. Numbers on each lane represent p21WAF1
protein levels determined as described in Methods. (TIFF 222 kb)
Additional file 10: Figure S10. Analysis of adipogenic markers
expression in ERBB2+ BC cells. Cells were cultured for 7d with control
medium (Ctr), CA, Tz or CA + Tz supplemented medium, which was
changed every 48 h. A) PLIN1 and PLIN2 mRNA expression levels were
detect by RT qPCR analysis and are expressed as arbitrary units (A.U.).
Mean values and standard deviation (indicated as vertical bars) from
three independent replicates (n = 3) are shown. P < 0.05 (*), P < 0.01 (**).
B) A representative immunoblot analysis is shown, which was performed
with an anti-PPARγ antibody on whole cell lysates. Tubulin is shown as
loading control. Numbers on each lane represent PPARγ protein levels
determined as described in Methods. (TIFF 372 kb)
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